致编辑的信：对“LI-RADS形态学类型预测肝细胞癌根治性切除术后患者的预后”的评论 - Suppr

Letter to the Editor: Comment on: "LI‑RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".

作者信息

Ren Qian, Wang Yanjun

机构信息

Department of Urology Surgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.

Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.

出版信息

Ann Surg Oncol. 2023 Dec;30(13):8023-8024. doi: 10.1245/s10434-023-14444-w. Epub 2023 Oct 12.

DOI:10.1245/s10434-023-14444-w

PMID:37823969

Abstract

摘要

相似文献

Letter to the Editor: Comment on: "LI‑RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".致编辑的信：对“LI-RADS形态学类型预测肝细胞癌根治性切除术后患者的预后”的评论

Ann Surg Oncol. 2023 Dec;30(13):8023-8024. doi: 10.1245/s10434-023-14444-w. Epub 2023 Oct 12.

Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward.致编辑的信：中晚期肝细胞癌肝切除与化疗栓塞术的比较：迈向未来的评论

Hepatology. 2019 Jul;70(1):446-447. doi: 10.1002/hep.30409.

Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.致编辑的信：“中期肝细胞癌切除术后预后良好患者的识别”

Int J Surg. 2024 Sep 1;110(9):5916-5917. doi: 10.1097/JS9.0000000000001681.

Author response to Letter to the Editor: 'Are inflammation-based models feasible tools in predicting the outcome of patients with hepatocellular carcinoma?'.作者对致编辑的信的回复：“基于炎症的模型是预测肝细胞癌患者预后的可行工具吗？”

Liver Int. 2020 Jun;40(6):1499-1500. doi: 10.1111/liv.14397. Epub 2020 Feb 19.

Reply to the Letter to the Editor: Oncological benefit of anatomic resection for patients with hepatocellular carcinoma.致编辑的信的回复：肝细胞癌患者解剖性切除的肿瘤学获益

Surg Today. 2023 Oct;53(10):1217. doi: 10.1007/s00595-023-02735-4. Epub 2023 Aug 14.

Letter to editor: Does age effect on the short- and long-term outcomes of patients undergoing liver resection for hepatocellular carcinoma?

Eur J Surg Oncol. 2022 Apr;48(4):933-934. doi: 10.1016/j.ejso.2022.01.006. Epub 2022 Jan 7.

Letter to the Editor: Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Benefit or Not.致编辑的信：门静脉癌栓的肝细胞癌患者行肝切除术：是否有益

Hepatology. 2019 Nov;70(5):1877-1878. doi: 10.1002/hep.30872.

Inflammation in Hepatocellular Carcinoma Patients Undergoing Hepatectomy: An Important Target for Ongoing Study : Editorial Comment on "The Impact of Histological Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma".接受肝切除术的肝细胞癌患者的炎症：正在进行研究的一个重要靶点：对“组织学肝脏炎症对接受肝细胞癌肝切除术患者的肿瘤学及预后的影响”的编辑评论

Ann Surg Oncol. 2022 Apr;29(4):2148-2149. doi: 10.1245/s10434-022-11334-5. Epub 2022 Feb 4.

Letter to the Editor: Predicting Survival After Hepatocellular Carcinoma Resection Using Deep-Learning on Histological Slides.致编辑的信：利用深度学习对组织学切片进行肝细胞癌切除术后生存预测

Hepatology. 2021 May;73(5):2077-2078. doi: 10.1002/hep.31543.

Letter: sex disparity in prognosis of patients with hepatocellular carcinoma after resection.信函：肝细胞癌切除术后患者预后的性别差异

Aliment Pharmacol Ther. 2020 Dec;52(11-12):1767-1768. doi: 10.1111/apt.16089.

本文引用的文献

LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection.LI-RADS 形态学类型预测肝癌患者根治性切除术后的预后。

Ann Surg Oncol. 2023 Aug;30(8):4876-4885. doi: 10.1245/s10434-023-13494-4. Epub 2023 May 3.

Predictors of early and late hepatocellular carcinoma recurrence.预测早期和晚期肝细胞癌复发的因素。

World J Gastroenterol. 2023 Feb 28;29(8):1243-1260. doi: 10.3748/wjg.v29.i8.1243.

Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.根治性切除术后肝细胞癌的辅助治疗策略。

Front Med. 2021 Apr;15(2):155-169. doi: 10.1007/s11684-021-0848-3. Epub 2021 Mar 23.

Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.建立术前和术后模型以预测肝癌切除术后早期复发。

J Hepatol. 2018 Dec;69(6):1284-1293. doi: 10.1016/j.jhep.2018.08.027. Epub 2018 Sep 18.

Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial.抗病毒治疗降低低 HBV-DNA 水平肝癌患者的复发率：一项随机对照试验。

Ann Surg. 2018 Dec;268(6):943-954. doi: 10.1097/SLA.0000000000002727.

Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.经动脉化疗栓塞术辅助治疗 HBV 相关肝细胞癌切除术后：一项随机对照研究。

Clin Cancer Res. 2018 May 1;24(9):2074-2081. doi: 10.1158/1078-0432.CCR-17-2899. Epub 2018 Feb 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the Editor: Comment on: "LI‑RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献